United States Patent 8,778,390: Scope, Claim Boundaries, and US Patent Landscape for Methylphenidate 12-Hour Aqueous Extended-Release Oral Suspension
What is US Patent 8,778,390 about and what is the core claim scope?
Answer: US 8,778,390 is directed to an aqueous methylphenidate extended-release (about 12 hours) oral suspension with (i) an immediate-release methylphenidate component and (ii) a sustained-release methylphenidate component built from a barrier-coated, water-insoluble, water-permeable, pH-independent methylphenidate-ion exchange resin complex, plus (iii) room-temperature physical/chemical stability and (iv) tight pharmacokinetic (PK) ranges for racemic methylphenidate and (optionally) d-methylphenidate following a defined dose-equivalent administration.
Core inventive constraints embedded in the independent claim (Claim 1)
Claim 1 sets four technical “gates” that jointly narrow infringement:
- Dosage form architecture
- “methylphenidate aqueous extended release oral suspension”
- includes immediate release component and sustained release component
- includes water
- Stability at room temperature
- “stable at room temperature for at least one month”
- PK target for about 12 hours
- “single mean average plasma concentration peak”
- “therapeutically effective plasma profile for about 12 hours”
- Quantitative PK ranges for an adult single oral administration
- dose equivalent: 60 mg racemic methylphenidate HCl
- AUC0-∞: ~114 to 180 ng·hr/mL
- Cmax: ~11 to 17 ng/mL
- Tmax: ~4 to 5.25 hours
- T1/2: ~5 to 7 hours
If any one of these gates fails, claim 1 is not met.
How do claims 1 and 23 compare (60 mg vs 72 mg PK windows and buffering inclusion)?
Answer: Claim 23 is a closely related claim set with different dose-equivalent context (72 mg) and different PK windows, and it explicitly recites a buffering agent. Claim 1 recites the 60 mg PK window and does not require a buffering agent in the independent claim.
Claim 1 (60 mg dose-equivalent) vs Claim 23 (72 mg dose-equivalent)
| Element |
Claim 1 |
Claim 23 |
| Dosage form |
Aqueous extended release suspension; immediate + sustained components |
Same architecture, but adds buffering agent requirement |
| Room temp stability |
≥ 1 month |
≥ 1 month |
| PK shape |
single mean peak; ~12 hr profile |
same concept |
| Dose-equivalent |
60 mg racemic MPH HCl in adults |
72 mg racemic MPH HCl in adults |
| AUC0-∞ |
114 to 180 ng·hr/mL |
137.2 to 214.4 ng·hr/mL |
| Cmax |
11 to 17 ng/mL |
13.6 to 21.3 ng/mL |
| Tmax |
4 to 5.25 hr |
3 to 5 hr |
| Buffering agent |
Not required in claim 1 |
Required (buffer selected from enumerated acids/salts; includes mixtures) |
Dependent claim precision
- Claim 2 refines d-methylphenidate PK (for the “60 mg” construct of claim 1) with a specific AUC/Cmax/Tmax/T1/2 datapoint window.
- Claims 24 refines PK again for the 72 mg construct of claim 23.
What patents protect the sustained-release core: barrier-coated methylphenidate-ion exchange resin complex?
Answer: Within 8,778,390 itself, the sustained-release element is tightly defined as:
- water-insoluble, water-permeable
- pH-independent
- barrier coated
- methylphenidate bound to an ion exchange resin complex
- barrier coated “over the methylphenidate-ion exchange resin complex”
This structure is then further limited by barrier-coating chemistry options and composition ranges.
Claim 3: sustained-release complex architecture
Claim 3 requires a specific class of sustained-release particles:
- barrier-coated methylphenidate-ion exchange resin complex
- pH-independent diffusion barrier
- coating “over” the resin complex
Claim 4: barrier coating material group
Claim 4 restricts to one of three barrier systems:
- Polyvinylacetate (PVA) + plasticizer, cured, water-permeable, water-insoluble, pH-independent, high tensile strength
- Ethylcellulose applied as a non-aqueous solution
- Acrylate based pH-independent barrier coat using methyl methacrylate polymer or copolymer
Claim 5 to 7: PVA + triacetin + stabilizer + sodium lauryl sulfate option
If PVA is used, Claim 5 and Claim 6 impose composition ranges:
- PVA: ~70–90% by weight
- plasticizer: ~2.5–15% by weight
- stabilizer: included (Claim 6): ~5–10%
- surfactant: ~0.1–1%, enumerated as sodium lauryl sulfate
- plasticizer specifically: triacetin (Claim 7)
Claim 8 to 12: matrix granulation layer over resin complex
Claim 8 adds a matrix concept:
- complex is in a matrix formed by granulation with hydrophilic or hydrophobic polymeric components
Claim 9–11 provide polymer content ranges:
- hydrophilic polymer component: ~5–20% by weight
- specific example: polyvinylpyrrolidone (Claim 10)
- hydrophobic polymer/co-polymer component: ~5–20% by weight
Claim 12 quantifies barrier coat amount via weight gain:
- cured barrier coat present such that ~20%–45% weight gain relative to complex-matrix
Claim 13: acrylate-based polymer system specificity
Claim 13 limits acrylate coat to a particular polymer system:
- poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonoethyl methacrylate chloride)
What patents protect the immediate-release component (uncoated resin complex) and its ratio?
Answer: Claim 14 locks the immediate-release component to:
- methylphenidate-ion exchange resin complex
- uncoated
Claim 15 adds a numeric ratio:
- immediate release: ~10–30 parts by weight
- sustained release: ~70–90 parts by weight
- based on total methylphenidate in suspension
Infringement sensitivity: uncoated vs coated immediate-release
If an accused product coats the immediate-release resin complex with any diffusion barrier (or uses a different immediate-release release mechanism), Claim 14 may not be met, even if the sustained-release particle is correct.
What role do water content and buffering play in claim coverage?
Answer: Water content is required in both independent claim sets; buffering is mandatory only in Claim 23 (and its dependent claims), not Claim 1.
Water content (Claim 16 and Claim 25)
- Claim 16: at least ~80% water by weight (for claim 1 family)
- Claim 25: at least ~80% water by weight (for claim 23 family)
Buffering agent (Claims 18–21 and 28–30)
Claim 18 enumerates buffering agents for claim 1 family dependent claims:
- citric acid / ascorbic acid / acetic acid / tartaric acid / phosphoric acid and corresponding salts
Claim 19 narrows to:
- sodium citrate + anhydrous citric acid (preferred pair)
Claim 20–21 impose potency/preservation metrics:
- < ~5% loss in potency over ≥ 4 months at room temperature
- stability at room temperature for at least 4 months
Claim 28–29 similarly cover buffering agent selection for claim 23 family:
- acids/salts enumerated
- sodium citrate + anhydrous citric acid (Claim 29)
What are the method-of-treatment claims and what do they cover?
Answer: The patent includes treatment method claims that tie clinical use to delivering the claimed suspension.
- Claim 22: method of treating patients by delivering a “methylphenidate twelve-hour extended release suspension according to claim 1”
- Claim 30: same concept for “suspension according to claim 23”
These are use/delivery claims. They do not change product structure but can expand enforcement when a product is used in the claimed dosing form and schedule.
What do the dependent PK claims (Claim 2 and Claim 24) add to the infringement picture?
Answer: They narrow to specific d-methylphenidate and 72 mg test conditions.
Claim 2: d-methylphenidate PK (60 mg construct)
- AUC0-∞: ~143.65 ng·hr/mL
- Cmax: ~13.61 ng/mL
- Tmax: ~5 hr
- T1/2: ~5.65 hr
All following single oral administration of the aqueous liquid suspension at a dose equivalent to 60 mg racemic methylphenidate HCl.
Claim 24: methylphenidate PK (72 mg construct)
- AUC0-∞: ~171.5 ng·hr/mL
- Cmax: ~17.0 ng/mL
- Tmax: ~3.77 hr
In practice, these “point” values make the claim coverage more exacting than the range-based independent claim limits.
How strong is the patent estate for this specific formulation class?
Answer: Based only on the claim text provided, US 8,778,390 is strong on product-mechanism specificity and PK-based performance, but its enforceability against design-arounds will hinge on whether an alternative product still:
- uses the same barrier-coated resin complex concept with the defined pH-independent barrier,
- uses the defined coating chemistries and composition/weight-gain limits,
- maintains the defined water content and stability properties,
- and lands within the stated PK parameters for the specified dose-equivalent studies.
Claim tightness map (highest to lowest constraint)
- PK window + single mean peak + ~12 hr profile (Claim 1/23): quantitative performance gate
- barrier-coated pH-independent water-permeable/water-insoluble resin complex (Claims 3–4): mechanism gate
- specific barrier materials or specific acrylate polymer system (Claims 4, 13; PVA composition in Claims 5–7)
- matrix granulation component and barrier weight gain (Claims 8–12)
- immediate-release uncoated resin complex + ratio (Claims 14–15)
- water ≥80% (Claims 16, 25)
- buffering agent and potency loss at room temperature (Claim 23 dependents)
This structure suggests meaningful design-around risk for generic or reformulation efforts that change resin loading, coating grade/processing, particle size, immediate-release coating state, or formulation water system.
What generic entry risks exist for methylphenidate 12-hour aqueous extended-release suspensions?
Answer: The major generic entry risk under 8,778,390 is PK-driven infringement. Even when an applicant uses a similar resin-coating concept, small changes in coating thickness, plasticizer fraction, surfactant/stabilizer levels, granulation polymers, or buffer system can shift Cmax/Tmax/AUC outside the claim windows.
Likely infringement “hot spots” in an ANDA-style formulation
- Achieving single mean average plasma peak with the required Tmax range.
- Matching AUC0-∞ and Cmax ranges for 60 mg and/or 72 mg constructs.
- Reproducing the exact barrier coat chemistry (PVA/triacetin or ethylcellulose or the specified acrylate polymer).
- Matching the barrier coating weight gain (20%–45%).
- Maintaining room-temperature stability and water content ≥80%.
How would a Paragraph IV (or equivalent) challenge typically attack this patent’s scope?
Answer: Based on claim structure, a challenger would most plausibly argue non-infringement by:
- demonstrating a different sustained-release mechanism (e.g., non barrier-coated approach, different pH dependence, or different resin complex behavior),
- using a differently defined barrier system not covered by Claim 4 (or not meeting PVA/ethylcellulose/acrylate definition),
- failing the claimed PK windows (with clinical bioequivalence showing out-of-range values),
- or showing instability/potency loss beyond the claim conditions used by the patentee’s stability standards.
(Those are the only claim hooks visible from the provided text.)
US regulatory positioning: what does this patent imply for FDA exclusivity/Orange Book strategy?
Answer: 8,778,390 is a formulation/performance patent. For FDA product developers, it typically functions as an IP barrier to “same-dosage-form” competition unless the generic can show non-infringement or invalidity as to the listed claims.
Because this analysis is confined to the claim text supplied, no Orange Book listing, filing dates, or listed drug-product identity can be asserted here.
What is the practical claim coverage by dosage strength, dosing paradigm, and PK test settings?
Answer: Coverage is anchored to adult single-dose administration with dose equivalents tied to racemic methylphenidate HCl:
- 60 mg test condition for Claim 1 family
- 72 mg test condition for Claim 23 family
So, a competing suspension that is dose-formulated differently or tested under materially different dosing assumptions may not map cleanly to the claimed PK windows, even if it provides 12-hour coverage.
Key Takeaways
- US 8,778,390 claims a specific aqueous methylphenidate 12-hour extended-release suspension design combining immediate-release and sustained-release resin complexes.
- The sustained-release component is the core: a barrier-coated, water-insoluble, water-permeable, pH-independent methylphenidate-ion exchange resin complex.
- Infringement is gated by quantitative PK windows and a single mean peak requirement, with distinct windows for 60 mg (Claim 1/2) and 72 mg (Claim 23/24) dose-equivalent settings.
- Barrier coating chemistry is constrained: PVA/triacetin or ethylcellulose or a defined acrylate system; PVA-dependent claims include detailed composition ranges and barrier weight gain limits.
- Immediate-release coverage requires uncoated resin complex and a defined resin-weight ratio to the sustained-release portion.
- Buffering and long-term room-temperature potency/stability limitations expand the dependent-claim reach, especially in the Claim 23 family.
FAQs
-
Does US 8,778,390 cover dexmethylphenidate-only suspensions or only racemic methylphenidate?
The claims allow dexmethylphenidate selection in immediate and/or sustained components, and Claim 2 includes d-methylphenidate PK, but Claim 1/23 are anchored to racemic dose-equivalent administration in the stated PK ranges.
-
What coating changes are most likely to avoid Claim 3/4 infringement?
Substituting a sustained-release mechanism that is not a barrier-coated, pH-independent, water-permeable/water-insoluble resin complex, or using barrier chemistries outside the enumerated options.
-
How can a product stay in the “12-hour” label but still avoid infringement?
By shifting PK metrics (AUC, Cmax, Tmax, T1/2) outside the specific windows required by the claims for the defined adult dosing conditions.
-
Is room-temperature stability only a dependent limitation or an independent gate?
It is an independent gate in Claim 1 and Claim 23 because both require stability at room temperature for at least one month.
-
Which claim elements are most sensitive to formulation manufacturing variables?
Barrier coat composition (PVA/plasticizer/stabilizer/surfactant), barrier weight gain (20%–45%), polymer matrix content (5%–20%), and the resulting particle release kinetics that drive the clinical PK windows.
References
- US Patent 8,778,390 (claims as provided in prompt).
